What is glycogen storage?
Glycogen storage is the synthesis and retention of glycogen, the branched glucose polymer that serves as the body's short-term carbohydrate reserve. This page summarises what the research literature and registered study
Glycogen storage is the process by which glucose is polymerised into glycogen, a highly branched polymer of glucose units, and retained within cells — principally skeletal muscle and liver — as a short-term carbohydrate reserve. The term is used both for the biochemical act of glycogen synthesis (glycogenesis) and for the resulting pool of stored glycogen measured in a tissue. In the research literature the concept appears under several related labels: muscle glycogen storage, hepatic glycogen storage, glycogen synthesis, and glycogen repletion. The evidence block for this page does not supply a CAS number, sequence, molecular formula or molecular weight for glycogen, so none is stated here.
The work summarised below centres on glucose-handling pathways and their regulation — including glucokinase activation, insulin-independent hepatic glucose metabolism, and the partitioning of glucose between oxidation, storage and biomass synthesis — rather than on a single receptor family.
Research Studies
hCG, IGF-I and glycogen storage in doping-control analysis
A technical note described the development of a UHPLC-MS/MS method for the analysis of human chorionic gonadotropin (hCG) and insulin-like growth factor I (IGF-I) from dried blood spots, in a preliminary study [1]. The authors noted that both hormones are included on the WADA list of banned molecules. In their framing, male athletes may use pharmaceutical preparations of hCG to stimulate testosterone production before competition, and IGF-I to stimulate muscle protein synthesis, promote glycogen storage, and improve lipolysis [1]. The glycogen-storage claim here is contextual — it describes a rationale attributed to athlete use, not a measured outcome of the analytical method itself. The study's stated focus was dry matrix microsampling and dried blood spots as strategies to improve doping-control activities, including compound stability, simplification of sample collection and pre-analytic phases, and facilitation of automation [1].
Dorzagliatin and hepatic glycogen storage in pancreatic insufficient cystic fibrosis
A registered clinical trial protocol describes a study designed to determine the pharmacokinetic and pharmacodynamic response to dorzagliatin 50 mg twice daily after 7-day administration in individuals with pancreatic insufficient cystic fibrosis and abnormal glucose tolerance, compared with randomised, double-blind 7-day placebo administration in a cross-over fashion [2]. The stated hypothesis is that dorzagliatin administration will result in significant drug concentrations and improved glucose tolerance, early-phase insulin secretion, glucagon suppression, and hepatic glycogen storage, assessed during a standardised mixed-meal tolerance test [2]. Hepatic glycogen storage is therefore an endpoint proposed in the protocol's hypothesis rather than a reported result. The population named is adults with pancreatic insufficient cystic fibrosis and abnormal glucose tolerance.
Muscle glycogen storage and maximal fat oxidation during exercise
A registered study protocol on maximal fat oxidation and fuel use during exercise states that fat and carbohydrate are the two main energy stores available as fuel during exercise, and that exercise intensity and feeding status are the major factors determining which fuel is used [3]. During prolonged exercise at low to moderate intensity, fat is described as the primary fuel, and the protocol notes that studies have attempted to understand strategies to maximise muscle glycogen storage and elevate fat oxidation during exercise, with the aim of preserving limited muscle glycogen stores and thereby improving endurance performance [3]. The protocol defines maximal fat oxidation (MFO) as the highest rate of fat oxidation across all exercise intensities [3]. Muscle glycogen storage appears here as a target of performance-oriented strategies rather than as an intervention outcome reported in the evidence block.
Irisin gene delivery and hepatic glucose metabolism in Akita mice
A study examined whether the exercise-induced hormone irisin can directly regulate hepatic glucose metabolism and manage the diabetic phenotype under insulin-deficient conditions [4]. The work investigated irisin gene delivery and reported sustained amelioration of diabetes in Akita mice via insulin-independent regulation of hepatic glucose metabolism [4]. This is an animal model — the Akita mouse — and the findings should be read as animal-only. The evidence block does not provide quantitative glycogen values, so none are reported here.
Skeletal muscle biomass as a fate of glucose
A review addresses the traditional view of glucose as a substrate for ATP production and glycogen storage in skeletal muscle, and presents evidence that glucose also serves as a building block for biomass synthesis in proliferating muscle satellite (stem) cells and in hypertrophying skeletal muscle fibres, drawing parallels to anabolic processes [5]. This reframes glycogen storage as one of several competing fates for glucose within muscle rather than the sole storage endpoint. The evidence block characterises this as a review of evidence; it does not supply original measurements, and no numerical values are given here.
Comparing the evidence base
The table below summarises the tissue, model and status of the glycogen-storage-related claims across the sources.
| Source | Tissue / focus | Model or population | Status of glycogen-storage claim |
|---|---|---|---|
| [1] | Muscle (contextual) | Male athletes (described rationale) | Contextual rationale, not a measured outcome |
| [2] | Hepatic | Pancreatic insufficient cystic fibrosis with abnormal glucose tolerance | Protocol hypothesis / proposed endpoint |
| [3] | Skeletal muscle | Exercise protocols | Strategy target, not a reported outcome |
| [4] | Hepatic | Akita mice | Animal-only finding |
| [5] | Skeletal muscle | Review of satellite cells and hypertrophying fibres | Review-level synthesis |
Where the evidence is limited
- No source in the evidence block reports a quantitative glycogen concentration, synthesis rate or storage capacity.
- The hepatic glycogen storage claim in [2] is a hypothesis within a registered protocol, not a completed result.
- The irisin findings in [4] derive from an animal model and are not established in humans on the basis of this evidence.
- The biomass-synthesis perspective in [5] is presented as a review argument rather than primary measurement.
If you are reading this for personal health reasons
The materials discussed on this page are supplied for laboratory research use only, and we do not provide dosing, medical or health guidance of any kind. Nothing here is a recommendation to use any compound, and no outcome is promised or implied. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Technical note: Development of a UHPLC-MS/MS method for the analysis of hCG and IGF-I from dried blood spots: A preliminary study.
- [2] Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis.
- [3] Maximal Fat Oxidation and Fuel Use During Exercise.
- [4] Irisin Gene Delivery Elicits Sustained Amelioration of Diabetes in Akita Mice via Insulin-Independent Regulation of Hepatic Glucose Metabolism.
- [5] Skeletal muscle biomass as an underappreciated fate of glucose.